Form 4: Pediatrix Medical Group CFO Kasandra Rossi Receives Significant Equity Award, Aligns Interests with Shareholders

Pediatrix Medical Group's EVP, CFO, and Treasurer, Kasandra H. Rossi, was granted 26,502 restricted shares as part of an annual equity award, aligning her incentives with the company's long-term performance.

Summary

• Kasandra H. Rossi, EVP, CFO, and Treasurer of Pediatrix Medical Group, Inc. (MD), was granted 26,502 shares of common stock on June 1, 2025, as part of an annual equity award under the company's Amended and Restated 2008 Incentive Compensation Plan.
• These restricted shares will vest in three tranches: 25% on June 1, 2026, 25% on June 1, 2027, and the remaining 50% on June 1, 2028.
• Concurrently, 677 restricted shares were disposed of at a price of $14.15 per share on June 1, 2025, to cover tax obligations upon the vesting of other shares.
• Following these transactions, Ms. Rossi directly beneficially owns 76,976 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of a significant equity award to a key executive is generally positive as it aligns management's interests with shareholders and serves as a retention tool. The tax withholding is a neutral, standard procedure.

Positives

• The grant of 26,502 restricted shares to a key executive like the CFO aligns management's long-term interests with those of shareholders.
• The equity award is part of an annual incentive compensation plan, indicating a structured approach to executive remuneration and retention.

Negatives

• The disposition of 677 shares for tax withholding, while a standard practice, represents a reduction in the executive's immediate shareholding.

Future Outlook

The vesting schedule for the restricted shares extends through June 1, 2028, indicating a long-term incentive structure for the CFO, aligning her future compensation with the company's performance over the next three years.

Industry Context

This filing reflects standard executive compensation practices within the healthcare services industry, where equity awards are commonly used to incentivize and retain key management personnel, linking their financial success to the company's long-term value creation.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) with multi-year vesting schedules is a common practice for executive compensation across various industries, including healthcare, to promote long-term alignment between executives and shareholders.
• The specific vesting schedule (25%/25%/50% over three years) is within typical industry norms for annual equity grants to senior executives.
• The withholding of shares for tax purposes upon vesting is a standard and expected procedure for equity compensation.

Stakeholder Impact

• Shareholders: The grant of restricted shares may result in minor dilution but is intended to align the CFO's interests with long-term shareholder value creation.
• Employees: This transaction highlights the company's use of equity-based compensation, which can be a positive signal regarding employee incentive programs.
• Management: The CFO receives a significant long-term incentive, enhancing her financial alignment with the company's performance.

Next Steps

• Vesting of 25% of restricted shares on June 1, 2026.
• Vesting of another 25% of restricted shares on June 1, 2027.
• Vesting of the final 50% of restricted shares on June 1, 2028.

Key Dates

Keywords

Pediatrix Medical Group, MD, SEC Form 4, Insider Trading, Equity Award, Restricted Stock, Executive Compensation, Kasandra H. Rossi, CFO, Stock Grant, Vesting Schedule, Healthcare Services